At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
VIC- 1911drug
Likely dose
VIC- 1911 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Masonic Cancer Center, University of Minnesota·interventional·Posted Nov 15, 2021·Updated Dec 22, 2025
In Brief
A Phase 2 clinical trial evaluating VIC- 1911 for Acute Leukemia and 3 related conditions. Completed, enrolled 16 participants across 1 site.
Detailed Summary
This is a single-arm, phase I/II, study of PTCy/sirolimus plus VIC-1911 to prevent GVHD and relapse after Allogeneic Hematopoietic Cell Transplantation (alloHCT).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartMar 2022
Primary CompletionSep 2024
Study CompletionJun 2025
TodayJul 2026
First PostedNov 15, 2021
Enrollment StartMar 17, 2022
Primary CompletionSep 19, 2024
Study CompletionJun 30, 2025
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 4.6 years ago
Interventions
VIC- 1911drug
25 mg, 50 mg, or 75 mg administered twice a day from day 5 post HCT to day 45, and the dose escalation will stop once we identify the lowest biologically active and safe dose of VIC.